Every design choice buys one outcome and costs another, and the second half is stated rather than hidden. The highest-probability failure is partial price reform with full benefit expansion — a reversal of sign rather than a narrowed advantage. Geography imposes irreducible cost that no payment design removes; the correct category is universal service obligation. And nothing here follows automatically from single-payer financing: thirteen separate statutes are named, because assumed preconditions are how programs discover in year three that a load-bearing law was never passed.
Payment matched to cost structure funds standby capability and ends lane arbitrage. It costs four rule sets and four audit regimes.
Supply built before demand avoids the waiting-list failure. It costs early political payoff: voters pay years before receiving.
Abolishing prior authorization ends insurer discretion over the individual case. It costs prospective utilization control, so some unnecessary care is paid for.
A program that lists only its benefits is read as a sales document and discounted accordingly. Stating the cost of each choice is what makes the choice legible as a choice.
It also disciplines the design. A tradeoff that cannot be named is usually one that has not been thought through.
A standing public arm buys workforce, institutional memory and a constituency. It costs a permanent federal operating footprint and hundreds of chartered institutions to govern.
A universal floor buys equal entitlement and removes the state race to the bottom. It costs federal preemption, state financing discretion, and constitutional litigation.
Price convergence buys national affordability. It costs clinician income and provokes the hardest fight in the program.
The supplemental market buys choice and coalition durability. It costs visible inequality above the floor.
Regional chartering buys local fit. It costs national uniformity of operation and guarantees uneven competence.
Ending eligibility spend-down removes the cruelty of impoverishment as the price of care. It costs some public money reaching the affluent, recovered by contribution and estate.
Capability over presence buys real access. It costs local facility retention: some towns lose a hospital and gain a bundle.
A statutory cost-effectiveness corridor buys fiscal and clinical discipline in end-stage life-prolonging therapy. It costs the public exclusion of some effective treatments at some prices.
The frugal long-term-care launch buys durability. It costs continued family burden and defers a broader benefit.
The slow obstetric build buys safety and realism. It costs continued travel-time gaps during the transition, backstopped by funded transport.
Listing tradeoffs is a rhetorical move that inoculates against criticism without changing anything.
Only if the list is decorative. These are checkable: four audit regimes either exist or do not, the public footprint is either permanent or not, some towns either lose hospitals or do not. The test is whether the program still says these things when they become inconvenient.